Page results
-
A new research study at UCLH and UCL will investigate how a rare type of blood cancer develops and what types of treatment may be effective for patients.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
Researchers at UCLH and Imperial College Healthcare NHS Trust are to trial a new weight loss treatment which involves reducing blood supply to part of the stomach.
-
The Secretary of State for Health and Social Care, The Rt. Hon. Sajid Javid MP visited the National Hospital for Neurology and Neurosurgery (NHNN), earlier this week (Wednesday 4 May 2022).
-
This page provides details of your treatment pathway coordinator for the Teenage and Young Adult Cancer Service.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This information is for patients receiving steroids for immunotherapy toxicity.
File results
-
FOI/2023/0119 - Post occupancy evaluations following completion of a capital project
-
FOI/2023/0117 - EPRR Team contact information
-
FOI/2023/0115 - Deaths in A&E
-
FOI/2023/0114 - Electronic Patient Record/ Electronic Health Record systems
-
FOI/2023/0111 - Migraine treatment
-
FOI/2023/0110 - General anaesthesia paediatric dental waiting times
-
FOI/2023/0109 - UK-EU aggrement S2 funding applications and treatments
-
FOI/2023/0105 - Maternity services birthing centre
-
FOI/2023/0080 - Treatment for Myeloid leukaemia (AML) and chronic lymphocytic leukaemia
-
FOI/2023/0075 - Attrition rates for staff working in advanced practice roles